Updates in therapeutic drug monitoring in inflammatory bowel disease

Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM.

Automated summary

This review summarizes the latest data on therapeutic drug monitoring (TDM) in patients with inflammatory bowel disease on biologics and/or immunomodulators, discussing reactive and proactive TDM approaches to manage patients who do not respond well to these medications.